CA3240633A1 - Tryptamine prodrugs - Google Patents

Tryptamine prodrugs Download PDF

Info

Publication number
CA3240633A1
CA3240633A1 CA3240633A CA3240633A CA3240633A1 CA 3240633 A1 CA3240633 A1 CA 3240633A1 CA 3240633 A CA3240633 A CA 3240633A CA 3240633 A CA3240633 A CA 3240633A CA 3240633 A1 CA3240633 A1 CA 3240633A1
Authority
CA
Canada
Prior art keywords
alkyl
linear
compound
branched
co2h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240633A
Other languages
English (en)
French (fr)
Inventor
Nathan Bryson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reunion Neuroscience Inc
Original Assignee
Reunion Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reunion Neuroscience Inc filed Critical Reunion Neuroscience Inc
Publication of CA3240633A1 publication Critical patent/CA3240633A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3240633A 2021-12-14 2022-12-08 Tryptamine prodrugs Pending CA3240633A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289501P 2021-12-14 2021-12-14
US63/289,501 2021-12-14
PCT/CA2022/051797 WO2023108260A1 (en) 2021-12-14 2022-12-08 Tryptamine prodrugs

Publications (1)

Publication Number Publication Date
CA3240633A1 true CA3240633A1 (en) 2023-06-22

Family

ID=86775179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240633A Pending CA3240633A1 (en) 2021-12-14 2022-12-08 Tryptamine prodrugs

Country Status (6)

Country Link
US (1) US20250051278A1 (OSRAM)
EP (1) EP4448489A4 (OSRAM)
JP (1) JP2024546138A (OSRAM)
CN (1) CN118679146A (OSRAM)
CA (1) CA3240633A1 (OSRAM)
WO (1) WO2023108260A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL327334A (en) * 2020-02-04 2026-05-01 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders
JP7702654B2 (ja) * 2020-06-30 2025-07-04 リユニオン・ニューロサイエンス、インコーポレイテッド トリプタミンプロドラッグ
MX2023006997A (es) * 2020-12-18 2023-08-29 Compass Pathfinder Ltd Alcaloides de indol modificados para usos terapeuticos.

Also Published As

Publication number Publication date
JP2024546138A (ja) 2024-12-17
US20250051278A1 (en) 2025-02-13
WO2023108260A1 (en) 2023-06-22
EP4448489A1 (en) 2024-10-23
CN118679146A (zh) 2024-09-20
EP4448489A4 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
US11292765B2 (en) Tryptamine prodrugs
US20250051278A1 (en) Tryptamine prodrugs
KR100703103B1 (ko) 성기능 장애 치료용 알파-2-델타 리간드
WO2018133670A1 (zh) 丁苯酞-替米沙坦杂合物及其制备方法和用途
JP4832897B2 (ja) エステル誘導体及びその医薬用途
EP2382206A2 (en) Compounds and methods for the treatment of pain and other diseases
JP6321274B2 (ja) トリプル再取込み阻害剤及びそれらの使用方法
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
LU87129A1 (fr) Nouvel acide piperazinecarboxylique,sa preparation et son utilisation comme medicament
EP2917204B1 (fr) Derives de 1h-indole-3-carboxamide et leurs utilisation comme antagonistes du p2y12
HK40114112A (zh) 色胺前药
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
HK40114605A (zh) 色胺前药
HK40114252A (zh) 色胺前药
HK40091294A (zh) 色胺前药
HK40091294B (zh) 色胺前药
WO2011058943A1 (ja) Ｍｃｈ ｒ１アンタゴニスト活性を有する化合物とｎｐｙ ｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物
WO1997024030A1 (en) Pyrrolidine derivatives
JPWO1994018191A1 (ja) 新規なアミン誘導体

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241112

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124